Association of Adiponutrin/Patatin Like Phospholipase 3 (PNPLA3) I148M Gene Variant with Chronic Hepatitis C in Egyptian Children
Journal of Advances in Medicine and Medical Research,
Background: Chronic hepatitis C (CHC) represents a leading cause of liver-related mortality worldwide. The patatin-like phospholipase domain-containing 3 gene (PNPLA3/adiponutrin) rs738409 (I148M) single-nucleotide polymorphism (SNP) has been reported to be linked with the severity and progression of liver fat content and liver fibrosis in CHC among different racial groups. Such reports are lacking in CHC Egyptian children.
Aim of Study: To evaluate the possible association of PNPLA3-I148M gene variant with the severity of liver fat content and liver fibrosis in Egyptian children with CHC.
Patients and Methods: Fifty normal-weighted children (mean age 10.62±2.59 years) with CHC were subjected to genotyping of PNPLA3-I148M gene variant using the real time PCR TaqMan assay. FibroScan examination for assessment of both liver fibrosis by Fibroscan liver stiffness (LMS) and liver steatosis by the controlled attenuation parameter (CAP) scores and histological examination of liver biopsies for assessment of liver steatosis, and METAVIER scoring for necroinflammatory activity grades and liver fibrosis stages were done for all patients as well as appropriate laboratory investigations. APRI and FIB-4 indices as well as insulin resistance using HOMA-IR were also calculated.
Results: 34 cases (68%) had CC genotype (wild CC genotype) ,9 cases (18%) had CG genotype (heterozygous for the risk G allele) and 7 cases (14%) had GG genotype (homozygous for the risk G allele). Significant higher values of LSM and CAP steatosis scores were found in patients with CG and GG genotypes compared to those with CC genotype. CG gene variant and GG gene variant were significant positive predictive factors for histopathological liver steatosis and fibrosis stages and inflammatory activity grades among the studied patients. Significant higher values of many laboratory variables (AST, fasting blood glucose, fasting serum insulin, and HOMA-IR) but lower platelets count was found in patients with G allele (CG+ GG) compared to patients without G allele (CC). In addition, significant positive correlations between PNPLA3-I148M gene variant and indicators of hepatic steatosis and fibrosis and many laboratory parameters (AST, APRI, FIB4, FBS, fasting serum insulin, and HOMA-IR) but a significant negative correlation between PNPLA3-I148M gene variant and platelet cell count were found among the studied patients.
Conclusion: Data of this study suggested that polymorphisms in the PNPLA3 I148M gene variant could contribute to the severity of hepatic steatosis and fibrosis of the studied Egyptian children with CHC.
- Chronic hepatitis C
- liver fibrosis
- patatin like phospholipase 3 (PNPLA3) I148M gene.
How to Cite
Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57.
Indolfi G, Easterbrook P, Dusheiko GM, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):477-487.
Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33:106-115.
Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358-1364.
Akuta N, Suzuki F, Tsubota A, et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: Therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol. 2002;37:831-836.
Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002;37:837-842.
Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology. 2006;130: 1636–1642.
Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology. 2006;44: 1648-1655.
Cua IH, Hui JM, Kench JG, et al. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology. 2008;48: 723-731
Czaja AJ, Carpenter HA, SantrachPJ, et al. Host- and disease specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29:198-206.
Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002;36:729-73.
Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36:1266-1272.
Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 2002;122:352-365.
Valenti L, Pulixi E, Fracanzani AL, et al. TNF-alpha genotype affects TNF-alpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol. 2005;43:944-950.
Valenti L, Pulixi EA, Arosio P, et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Hematologica. 2007;92:1037-1042.
Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–65.
Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009;52:1056–60.
Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain–containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52:1274-80.
Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the PNPLA3 / adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209-1217.
Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011; 53(3), 791–799.
Trépo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54(1):60–69
Cai T, Dufour JF, Muellhaupt B et al. Viral genotype specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J. Hepatol. 2011;55(3):529–535.
Valenti L, Alisi A, and Nobili V. I148M PNPLA3 variant and progressive liver disease: A new paradigm in Hepatology. Hepatology. 2012;56:1883-9.
Valenti L, Aghemo A, Stattermayer AF, et al. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol. Ther. 2012;35(12),1434–1442.
He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPlA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285(9):6706-15.
Pirazzi C, Adiels M, Burza MA et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J. Hepatol. 2012;57(6):1276–1282.
Trépo E, Romeo S, Zucman-Rossi J, et al. PNPLA3 gene in liver diseases. Journal of hepatology. 2016;65(2):399-412.
Rembeck K and Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics.2015; 16(10):1179-88.
Egyption growth curves: Diabetes and Endocrine Metabolism, Pediatric Unit Cairo University Children's Hospital.
Accessed on October 23, 2016.
Bailisteri WF, Shaw LM. Liver functions. In: Balisteri WF (ed.): Fundamental of Clinical Chemistery.3rd ed. WB Saunders Company, Philadelphia. 1987;729-899.
Wallance TM, Levy JC, Mattlewes DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27:1487-95.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2006;43:1317-1325.
Yilmaz Y, Yonal O, Kurt R, et al. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease. Hepat Mon. 2011;11:103-107.
Giuliano IC, Caramelli B, Pellanda L, et al. Da Aterosclerose Na Infância E Na Adolescência. Arq Bras Cardiol. 2005; 85:1-36.
Cardoso AS, Gonzaga NC, Medeiros CC, et al. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents. J Pediatr. 2013;89(4):412–418.
Krawczyk M, Grünhage F, Zimmer V, et al. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J hepatol. 2011;55(2):299-306.
Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: A new non-invasive method for assessment of hepatic ﬁbrosis. Ultrasound Med Biol. 2003;29(12):1705–1713.
Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.
De Ledinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelet ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr. 2007;45(4):443-450.
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41:48-54.
Sasso M, Beaugrand M, de Ledinghen V et al. Controlled attenuation parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35.
Sasso M, Miette V, Sandrin L, et al. The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36:13-20.
Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C. J Viral Hepat. 2012;19(4):244 -53.
Lefkowitch, JH. Liver biopsy assessment in chronic hepatitis. Arch Med Res. 2007;38:634-64.
Goodman, ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds‐C Trial. Hepatology. 2008;47(3):836-843.
The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15-20.
Bedossa P, Poynard T, and the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hematology. 1996;24: 289-293.
Dawson BD, Trapp RG: Reading the medical literature: Basic & Clinical Biostatistics. Lange Medical Book/ McGraw – Hill. Medical Publication Division, New York. 3rd ed., Ch. 2001;7-9:161-218 and Ch. 13, PP 305-314.
Petrie A, Sabin C. Rates and Poisson Regression. Medical Statistics at a Glance. 2nd Edition. Blackwell Publishing Ltd, Oxford, UK; 2005.
Mackawy AM, Badawi ME, Megahed O. Patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism and liver damage in chronic hepatitis C Egyptian patients. Egyptian Journal of Medical Human Genetics. 2015;16(4):333-41.
Purcell RH, Alter HJ, and Dienstag JL. Non-A, non-B hepatitis. 1976. Yale J Biol Med. 2000;73:175-182.
Zhang H, Xue L, Chen L, et al. A meta-analysis of the association between the I148M variant of Patatin-Like Phospholipase Domain Containing 3 gene and the presence of chronic hepatitis C. Hepat Mon. 2015;15(11): e31987
Manchiero C, da Silva Nunes AK, Magri MC, et al. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. BMC Infect dis. 2017;17(1):780.
Petta S, Vanni E, Bugianesi E, et al. PNPLA 3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther. 2015;41(10):939-48.
Giannini F, Botta F, Borro P, et al. Platelet count/spleen diameter ratio; proposal and validation of a noninvasive parameter to predict the presence of esophageal varices in patients with liver cirrhosis. Gut. 2003;52:1200-5.
Baranova A, Lal P, Birerdinc A, et al. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91.
Nakaoka K, Hashimoto S, Kawabe N, et al. PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients. Springer Plus. 2015;4(1):83.
Crisan D, Grigorescu M, Crisan N, et al. Association between PNPLA3 [G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus-genetics matters. Journal of Physiology and Pharmacology. 2019;70(4):585-93.
Li Y, Xing C, Tian Z, et al. Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population. BMC medical genetics. 2012;13(1):113.
Hotta K, Yoneda M, Hyogo H, al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet. 2010;11:172.
Sato M, Kato N, Tateishi R, et al. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res. 2014;44(10):E137–44.
Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738-744.
Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology; 29:1215-1219.
Narita R, Abe S, Kihara Y, et al. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol. 2004;41(1):132–138.
Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416–23.
Taskoparan M, Serin E, Gokturk HS et al. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C. Hepatogastroenterology. 2011;58:875–879.
Rembeck K, Maglio C, Lagging M, et al. PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet. 2012;13(1):82.
Wang CW, Lin HY, Shin SJ, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011;31(9):1326–1331.
Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865-872.
Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58:2616–23.
Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatinlike phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology. 2010;52(4):1281–1290.
Sevastianova K, Kotronen A, Gastaldelli A, et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr. 2011;94(1):104–111.
Romeo S, Sentinelli F, Dash S, et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond). 2010;34(1):190–194.
Romeo S, Sentinelli F, Cambuli VM, et al. The 148 M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol. 2010;53(2):335–338.
Speliotes EK, Butler JL, Palmer CD, et al, PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904- 912.
Stattermayer AF, Rutter K, Beinhardt S, et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol. 2012;57:492- 498.
Huang CF, Dai CY, Yeh ML, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015,2012;62:512– 18.
Fan JH, Xiang MQ, Li QL, et al. PNPLA3 rs738409 polymorphism associated with hepatic steatosis and advanced fibrosis in patients with chronic hepatitis C virus: A meta-analysis. Gut and Liver. 2016;10(3):456.
Huang CM, Chang KC, Hung CH, et al. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PloS one. 2017;12(8):e0182204.
Shen JH, Li YL, Li D, et al. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res. 2015;56(1):167-75.
Agundez JA, GarcõÂa-Martin E, Maestro ML, et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One. 2012;7:e37998.
Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Gent. 2014;23:4077–85.
Yasui K, Kawaguchi T, Shima,T, et al. Effect of PNPLA3 rs738409 variant (I148M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C. J Gastroenterol. 2015;50(8):887- 893.
Dunn W, Vittal A, Zhao J, et al. PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis. BMJ open gastroenterol. 2019;6(1): e000241.
Linden D, Ahnmark A, Pingitore P, et al. PNPLA3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in PNPLA3 I148M knock-in mice. Mol Metab. 2019;22:49-61.
Abstract View: 173 times
PDF Download: 67 times